XML 53 R13.htm IDEA: XBRL DOCUMENT v3.19.3
Leases
9 Months Ended
Sep. 30, 2019
Leases [Abstract]  
Leases
Leases

The Company leases most of its retail stores and mail order facilities and certain distribution centers and corporate offices under operating or finance leases, typically with initial terms of 15 to 25 years. The Company also leases certain equipment and other assets under operating or finance leases, typically with initial terms of 3 to 10 years.

The Company maintains certain lease agreements for which the noncancelable contractual term of the pharmacy lease arrangement exceeds the remaining estimated economic life of the buildings being leased. For these pharmacy lease agreements, the Company concluded that for accounting purposes the lease term was the remaining economic life of the buildings. Consequently, most of these individual pharmacy leases are finance leases.

The following table is a summary of the Company’s components of net lease cost for the three and nine months ended September 30, 2019:
In millions
Three Months Ended September 30, 2019
 
Nine Months Ended September 30, 2019
Operating lease cost
$
681

 
$
2,044

Finance lease cost:
 
 
 
Amortization of right-of-use assets
9

 
27

Interest on lease liabilities
11

 
32

Total finance lease costs
20

 
59

Short-term lease costs
5

 
17

Variable lease costs
148

 
434

Less: sublease income
13

 
35

Net lease cost
$
841

 
$
2,519


Supplemental cash flow information related to leases for the nine months ended September 30, 2019 is as follows:
In millions
 
Cash paid for amounts included in the measurement of lease liabilities:
 
Operating cash flows paid for operating leases
$
2,023

Operating cash flows paid for interest portion of finance leases
32

Financing cash flows paid for principal portion of finance leases
19

Right-of-use assets obtained in exchange for lease obligations:
 
Operating leases
1,203

Finance leases
82



Supplemental balance sheet information related to leases as of September 30, 2019 is as follows:
In millions, except lease term and discount rate
 
Operating leases:
 
Operating lease right-of-use assets
$
20,757

 
 
Current portion of operating lease liabilities
$
1,798

Long-term operating lease liabilities
18,826

Total operating lease liabilities
$
20,624

 
 
Finance leases: (1)
 
Property and equipment, net
$
560

 
 
Current portion of long-term debt
$
27

Long-term debt
591

Total finance lease liabilities
$
618

 
 
Weighted average remaining lease term
 
Operating leases
13.8

Finance leases
20.6

 
 
Weighted average discount rate
 
Operating leases
4.6
%
Finance leases
7.3
%
_____________________________________________ 
(1)
Finance lease right-of-use assets are included within property and equipment, net and the respective finance lease liabilities are included in current portion of long-term debt and long-term debt on the unaudited condensed consolidated balance sheets.

The following table summarizes the maturity of lease liabilities under finance and operating leases as of September 30, 2019:
In millions
Finance
Leases
 
Operating
Leases
(1)
 
Total
2019 (remaining three months)
$
18

 
$
679

 
$
697

2020
70

 
2,688

 
2,758

2021
68

 
2,567

 
2,635

2022
64

 
2,408

 
2,472

2023
62

 
2,297

 
2,359

Thereafter
883

 
17,165

 
18,048

Total lease payments (2)
1,165

 
27,804

 
28,969

Less: imputed interest
(547
)
 
(7,180
)
 
(7,727
)
Total lease liabilities
$
618

 
$
20,624

 
$
21,242


_____________________________________________ 
(1)
Future operating lease payments have not been reduced by minimum sublease rentals of $320 million due in the future under noncancelable subleases.
(2)
The Company leases pharmacy and clinic space from Target Corporation. Amounts related to such finance and operating leases are reflected above. Pharmacy lease amounts due in excess of the remaining estimated economic life of the buildings of approximately $2.3 billion are not reflected in this table since the estimated economic life of the buildings is shorter than the contractual term of the pharmacy lease arrangement.

The Company finances a portion of its store development program through sale-leaseback transactions. The properties are generally sold at net book value, which generally approximates fair value, and the resulting leases generally qualify and are accounted for as operating leases. The operating leases that resulted from these transactions are included in the table above. The Company does not have any retained or contingent interests in the stores and does not provide any guarantees, other than a guarantee of lease payments, in connection with the sale-leaseback transactions. Sale-leaseback transactions resulted in an
immaterial gain and proceeds of $5 million in the nine months ended September 30, 2019. There were no sale-leaseback transactions in the three months ended September 30, 2019 or the three and nine months ended September 30, 2018.

Store Rationalization Charges

During the first quarter of 2019, the Company performed a review of its retail stores and determined it would close 46 underperforming retail pharmacy stores during the second quarter of 2019. As a result, management determined that there were indicators of impairment with respect to the impacted stores, including the associated operating lease right-of-use assets. Accordingly, an interim long-lived asset impairment test was performed. The results of the impairment test indicated that the fair value of each store asset group was lower than the carrying value. The fair value was determined using a discounted cash flow method based on estimated sublease income. In the three months ended March 31, 2019, the Company recorded a store rationalization charge of $135 million, primarily related to these operating lease right-of-use asset impairment charges, which was recorded within operating expenses in the Retail/LTC segment.

During the third quarter of 2019, in connection with its annual budgeting process, the Company performed an updated review of its retail stores and determined it would close an additional 22 underperforming retail pharmacy stores during the first quarter of 2020. As a result, management determined that there were indicators of impairment with respect to the impacted stores, including the associated operating lease right-of-use assets. Accordingly, an interim long-lived asset impairment test was performed. The results of the impairment test indicated that the fair value of each store asset group was lower than the carrying value. The fair value was determined using a discounted cash flow method based on estimated sublease income. In the three months ended September 30, 2019, the Company recorded a store rationalization charge of $96 million, primarily related to these operating lease right-of-use asset impairment charges, which was recorded within operating expenses in the Retail/LTC segment.
Leases
Leases

The Company leases most of its retail stores and mail order facilities and certain distribution centers and corporate offices under operating or finance leases, typically with initial terms of 15 to 25 years. The Company also leases certain equipment and other assets under operating or finance leases, typically with initial terms of 3 to 10 years.

The Company maintains certain lease agreements for which the noncancelable contractual term of the pharmacy lease arrangement exceeds the remaining estimated economic life of the buildings being leased. For these pharmacy lease agreements, the Company concluded that for accounting purposes the lease term was the remaining economic life of the buildings. Consequently, most of these individual pharmacy leases are finance leases.

The following table is a summary of the Company’s components of net lease cost for the three and nine months ended September 30, 2019:
In millions
Three Months Ended September 30, 2019
 
Nine Months Ended September 30, 2019
Operating lease cost
$
681

 
$
2,044

Finance lease cost:
 
 
 
Amortization of right-of-use assets
9

 
27

Interest on lease liabilities
11

 
32

Total finance lease costs
20

 
59

Short-term lease costs
5

 
17

Variable lease costs
148

 
434

Less: sublease income
13

 
35

Net lease cost
$
841

 
$
2,519


Supplemental cash flow information related to leases for the nine months ended September 30, 2019 is as follows:
In millions
 
Cash paid for amounts included in the measurement of lease liabilities:
 
Operating cash flows paid for operating leases
$
2,023

Operating cash flows paid for interest portion of finance leases
32

Financing cash flows paid for principal portion of finance leases
19

Right-of-use assets obtained in exchange for lease obligations:
 
Operating leases
1,203

Finance leases
82



Supplemental balance sheet information related to leases as of September 30, 2019 is as follows:
In millions, except lease term and discount rate
 
Operating leases:
 
Operating lease right-of-use assets
$
20,757

 
 
Current portion of operating lease liabilities
$
1,798

Long-term operating lease liabilities
18,826

Total operating lease liabilities
$
20,624

 
 
Finance leases: (1)
 
Property and equipment, net
$
560

 
 
Current portion of long-term debt
$
27

Long-term debt
591

Total finance lease liabilities
$
618

 
 
Weighted average remaining lease term
 
Operating leases
13.8

Finance leases
20.6

 
 
Weighted average discount rate
 
Operating leases
4.6
%
Finance leases
7.3
%
_____________________________________________ 
(1)
Finance lease right-of-use assets are included within property and equipment, net and the respective finance lease liabilities are included in current portion of long-term debt and long-term debt on the unaudited condensed consolidated balance sheets.

The following table summarizes the maturity of lease liabilities under finance and operating leases as of September 30, 2019:
In millions
Finance
Leases
 
Operating
Leases
(1)
 
Total
2019 (remaining three months)
$
18

 
$
679

 
$
697

2020
70

 
2,688

 
2,758

2021
68

 
2,567

 
2,635

2022
64

 
2,408

 
2,472

2023
62

 
2,297

 
2,359

Thereafter
883

 
17,165

 
18,048

Total lease payments (2)
1,165

 
27,804

 
28,969

Less: imputed interest
(547
)
 
(7,180
)
 
(7,727
)
Total lease liabilities
$
618

 
$
20,624

 
$
21,242


_____________________________________________ 
(1)
Future operating lease payments have not been reduced by minimum sublease rentals of $320 million due in the future under noncancelable subleases.
(2)
The Company leases pharmacy and clinic space from Target Corporation. Amounts related to such finance and operating leases are reflected above. Pharmacy lease amounts due in excess of the remaining estimated economic life of the buildings of approximately $2.3 billion are not reflected in this table since the estimated economic life of the buildings is shorter than the contractual term of the pharmacy lease arrangement.

The Company finances a portion of its store development program through sale-leaseback transactions. The properties are generally sold at net book value, which generally approximates fair value, and the resulting leases generally qualify and are accounted for as operating leases. The operating leases that resulted from these transactions are included in the table above. The Company does not have any retained or contingent interests in the stores and does not provide any guarantees, other than a guarantee of lease payments, in connection with the sale-leaseback transactions. Sale-leaseback transactions resulted in an
immaterial gain and proceeds of $5 million in the nine months ended September 30, 2019. There were no sale-leaseback transactions in the three months ended September 30, 2019 or the three and nine months ended September 30, 2018.

Store Rationalization Charges

During the first quarter of 2019, the Company performed a review of its retail stores and determined it would close 46 underperforming retail pharmacy stores during the second quarter of 2019. As a result, management determined that there were indicators of impairment with respect to the impacted stores, including the associated operating lease right-of-use assets. Accordingly, an interim long-lived asset impairment test was performed. The results of the impairment test indicated that the fair value of each store asset group was lower than the carrying value. The fair value was determined using a discounted cash flow method based on estimated sublease income. In the three months ended March 31, 2019, the Company recorded a store rationalization charge of $135 million, primarily related to these operating lease right-of-use asset impairment charges, which was recorded within operating expenses in the Retail/LTC segment.

During the third quarter of 2019, in connection with its annual budgeting process, the Company performed an updated review of its retail stores and determined it would close an additional 22 underperforming retail pharmacy stores during the first quarter of 2020. As a result, management determined that there were indicators of impairment with respect to the impacted stores, including the associated operating lease right-of-use assets. Accordingly, an interim long-lived asset impairment test was performed. The results of the impairment test indicated that the fair value of each store asset group was lower than the carrying value. The fair value was determined using a discounted cash flow method based on estimated sublease income. In the three months ended September 30, 2019, the Company recorded a store rationalization charge of $96 million, primarily related to these operating lease right-of-use asset impairment charges, which was recorded within operating expenses in the Retail/LTC segment.